Category Archives: General HIV+ population

Stigma may contribute to HIV disparities for men who have sex with men (MSM). This systematic review quantified the effects of HIV stigma interventions for MSM on stigma and sex...

BACKGROUND: As infectious diseases approach global elimination targets, spatial targeting is increasingly important to identify community hotspots of transmission and effectively target interventions. We aimed to synthesise relevant evidence to...

Infective endocarditis (IE) causes substantial morbidity and mortality if untreated. The clinical course of IE might be different in HIV-positive patients as a result of immune dysfunction. This systematic review...

In the era of antiretroviral treatment, human immunodeficiency virus (HIV)-associated neurocognitive disorder (HAND) is common in HIV-positive (HIV+) patients, with an incidence of 30-50%. The relationship between education level and...

INTRODUCTION: Patients with chronic underlying diseases are more susceptible to coronavirus disease 2019 (COVID-19) complications. Recent studies showed people living with HIV (PLWH) are not at greater risk than the...

Direct-acting antivirals (DAAs) have been approved in recent years to treat patients infected by the Hepatitis C virus (HCV). The DAAs treatment is well tolerated and increases sustained virological response...

The World Health Organization 2030 targets for hepatitis C virus (HCV) elimination include diagnosing 90% of people with HCV and treating 80% of people diagnosed with HCV. This systematic review...

Introduction: Cumulative use of some first-generation protease inhibitors has been associated with higher rates of dyslipidemia and increased risk of cardiovascular disease. The protease inhibitors most commonly in use are...

There is a large body of evidence examining best practices, outcomes, impact, and other aspects of laboratory (non-rapid) HIV testing in emergency departments (EDs). Many studies have identified missed opportunities...

A 2019 systematic review identified several types of outcomes from scientific literature that guide assessment of SCS, including: usage by high-risk individuals, safe injection practice, overdose management, uptake of treatment...

Several studies analyze overall healthcare costs, pharmacy costs, and cost savings among people living with HIV relative to level of ART adherence. Generally, adherence to ART appears to predict levels...

As of 2017, the annual cost of single-tablet antiretrovirals (ART) in Ontario was estimated to be CAD 15,552 according to the Ontario Drug Benefit Formulary. Universal, no-cost ART for all...